Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Research article

Histopathologic features from preoperative biopsies to predict spread through air spaces in early-stage lung adenocarcinoma: a retrospective study

Authors: Lanqing Cao, Meng Jia, Ping-Li Sun, Hongwen Gao

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

Although spread through air spaces (STAS) is a robust biomarker in surgically resected lung cancer, its application to biopsies is challenging. Moreover, limited resection is not an effective treatment for STAS-positive lung adenocarcinoma. This study aimed to identify histologic features from preoperative percutaneous transthoracic needle biopsies (PTNBs) to predict STAS status in the subsequently resected specimens, and thus help in selecting the surgical extent.

Methods

Between January 2014 and December 2015, 111 PTNB specimens and subsequent resection specimens from consecutive lung adenocarcinoma patients were retrospectively examined. Histopathologic features of PTNB specimens and presence of STAS in subsequent resection specimens were evaluated and correlations between them were analyzed statistically.

Results

The study participants had a mean age of 59 years (range, 35–81) and included 50 men and 61 women. Thirty-six patients were positive for STAS whereas 75 were negative. The micropapillary/solid histologic subtypes of lung adenocarcinoma (26 of 39; 66.7%; P <  0.001), necrotic/tumor debris (31 of 42; 73.8%; P <  0.001), intratumoral budding (ITB) (20 of 33; 60.6%; P <  0.001), desmoplasia (35 of 41; 85.4%; P <  0.001), and grade 3 nuclei (12 of 14; 85.7%; P <  0.001) were more common in STAS-positive tumors. Micropapillary/solid histologic subtype (OR, 1.35; 95% CI: 1.06, 1.67), ITB (OR, 1.64; 95% CI: 1.09, 2.83), desmoplasia (OR, 1.83; 95% CI: 1.36, 3.12), and N stage (N1 stage: OR, 1.37; 95% CI: 1.19, 1.87) (N2 stage: OR, 1.29; 95% CI: 1.07, 1.73) were independent predictors of STAS.

Conclusions

Micropapillary/solid histologic subtype, ITB, and desmoplasia in preoperative PTNB specimens were independently associated with STAS in the subsequent resection specimens. Therefore, these can predict STAS and may help to optimize therapeutic planning.
Literature
6.
go back to reference Liu Y, Chen D, Qiu X, Duan S, Zhang Y, Li F, et al. Relationship between MTA1 and spread through air space and their joint influence on prognosis of patients with stage I-III lung adenocarcinoma. Lung cancer. 124:211–8. Liu Y, Chen D, Qiu X, Duan S, Zhang Y, Li F, et al. Relationship between MTA1 and spread through air space and their joint influence on prognosis of patients with stage I-III lung adenocarcinoma. Lung cancer. 124:211–8.
10.
go back to reference Bains S, Eguchi T, Warth A, Yeh YC, Nitadori JI, Woo KM, et al. Procedure-Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small i PS adenocarcinoma. Lung cancer 124:211-Adenocarcinomas. masbJ Thorac Oncol. 2019;14:72–86.CrossRef Bains S, Eguchi T, Warth A, Yeh YC, Nitadori JI, Woo KM, et al. Procedure-Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small i PS adenocarcinoma. Lung cancer 124:211-Adenocarcinomas. masbJ Thorac Oncol. 2019;14:72–86.CrossRef
21.
go back to reference Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2016;6:392–401.CrossRef Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2016;6:392–401.CrossRef
Metadata
Title
Histopathologic features from preoperative biopsies to predict spread through air spaces in early-stage lung adenocarcinoma: a retrospective study
Authors
Lanqing Cao
Meng Jia
Ping-Li Sun
Hongwen Gao
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-08648-0

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine